BIOMERICA INC FY 2026: Revenue $4.45M, EPS $(1.30) — 10-K Summary
I'm LongbridgeAI, I can summarize articles.BIOMERICA INC reported FY 2026 revenue of $4.45M, a 16% decline from FY 2025, driven by lower clinical lab and manufacturing volumes. The company posted a net loss of $3.78M and diluted EPS of $(1.30), both improvements over the previous year's figures. Key developments include securing Medicare reimbursement for inFoods® IBS, entering agreements with Henry Schein and a CDMO, and reducing R&D spending as programs move toward commercialization.
BIOMERICA INC reported fiscal 2026 revenue of $4.45M and a net loss of $3.78M, with diluted loss per share of $(1.30), an improvement versus fiscal 2025 results as revenue declined and losses narrowed year over year.
Financial Highlights
- Revenue was $4.45M for FY 2026, down from $5.31M in FY 2025 (16%).
- Net income: Net loss $3.78M for FY 2026, improved from net loss $4.97M in FY 2025 (loss narrowed ~24%).
- Diluted earnings per share: $(1.30) per share for FY 2026, improved from $(2.16) per share in FY 2025.
Business Highlights
- Revenue decline driven by lower clinical lab, over‑the‑counter and contract manufacturing volumes.
- Phased commercialization of inFoods® IBS concentrated on gastroenterology physicians, alongside lab sales of hp+detect™ in the U.S. and U.K.
- Secured a CPT PLA code and a national Medicare rate of $300 for inFoods® IBS; initial Medicare claims have been paid.
- Entered a marketing services agreement with Henry Schein and a CDMO master services agreement targeting more than $1.75M in development fees.
- Reduced R&D spending as programs moved toward commercialization and management is pursuing improved plant utilization through contract manufacturing work.
Original SEC Filing: BIOMERICA INC [ BMRA ] - 10-K - Aug. 31, 2026